The persistent expansion of the coronavirus disease 2019 (COVID-19) global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires the rapid development of safe and effective countermeasures to reduce transmission, morbidity, and mortality. Several highly efficacious vaccines are actively being deployed around the globe to expedite mass vaccination and control of COVID-19. Notably, viral vectored vaccines (VVVs) are among the first to be approved for global distribution and use. In this review, we examine the humoral, cellular, and innate immune responses elicited by viral vectors, and the immune correlates of protection against COVID-19 in preclinical and clinical studies. We also discuss the durability and breadth of immune response induced by VVVs and boosters. Finally, we present challenges associated with VVVs and offer solutions for overcoming certain limitations of current vaccine regimens. Collectively, this review provides the rationale for expanding the portfolio of VVVs against SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2, antibody, T cells, viral vectored vaccine, breath, 【초록키워드】 coronavirus disease, Coronavirus disease 2019, Vaccine, coronavirus, immune response, vaccination, Mortality, innate immune response, Transmission, severe acute respiratory syndrome Coronavirus, global pandemic, Viral, immune responses, morbidity, viral vectors, Clinical studies, respiratory, distribution, breadth, cellular, Safe, humoral, immune correlates, mass vaccination, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, rationale, regimens, limitation, viral vectored vaccines, offer, effective, caused, globe, approved, provide, reduce, elicited, immune correlate, 【제목키워드】 immunogenicity, fire, Fighting,